Cargando…

Thalidomide induces clinical remission and mucosal healing in adults with active Crohn’s disease: a prospective open-label study

BACKGROUND: Thalidomide is effective in inducing and maintaining clinical remission in children and adolescents with refractory Crohn’s disease (CD). However, little is known about the efficacy and safety of thalidomide for adult patients with CD. METHODS: We conducted a prospective open-label cohor...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Yao, Mao, Ren, Chen, Fang, Xu, Ping-Ping, Chen, Bai-Li, Wu, Yun, Qiu, Yun, Zhang, Sheng-Hong, Feng, Rui, Zeng, Zhi-Rong, Ben-Horin, Shomron, Chen, Min-Hu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415099/ https://www.ncbi.nlm.nih.gov/pubmed/28507598 http://dx.doi.org/10.1177/1756283X17698910

Ejemplares similares

Factors associated with the achievement of mucosal healing in Crohn’s disease: the benefit of endoscopic monitoring in treating to target
por: Mao, Ren, et al.
Publicado: (2017)

Mucosal Healing Is Associated With the Reduced Disabling Disease in Crohn's Disease
por: Huang, Shanshan, et al.
Publicado: (2019)

Normalization of C-Reactive Protein Predicts Better Outcome in Patients With Crohn's Disease With Mucosal Healing and Deep Remission
por: Lin, Xiaoqin, et al.
Publicado: (2020)

Correction to: Normalization of C-Reactive Protein Predicts Better Outcome in Patients With Crohn's Disease With Mucosal Healing and Deep Remission
por: Lin, Xiaoqing, et al.
Publicado: (2020)

Thalidomide induces mucosal healing in postoperative Crohn disease endoscopic recurrence: Case report and literature review
por: Hu, Huiqin, et al.
Publicado: (2016)

Different clinical outcomes in Crohn’s disease patients with esophagogastroduodenal, jejunal, and proximal ileal disease involvement: is L4 truly a single phenotype?
por: Mao, Ren, et al.
Publicado: (2018)

Risk Factors Associated with Impaired Ovarian Reserve in Young Women of Reproductive Age with Crohn’s Disease
por: Zhao, Yue, et al.
Publicado: (2020)

Thalidomide Combined With Azathioprine as Induction and Maintenance Therapy for Azathioprine-Refractory Crohn's Disease Patients
por: Li, Tong, et al.
Publicado: (2020)

Potential Utility of Therapeutic Drug Monitoring of Adalimumab in Predicting Short-Term Mucosal Healing and Histologic Remission in Pediatric Crohn's Disease Patients
por: Choi, So Yoon, et al.
Publicado: (2020)

Thalidomide-induced sinus bradycardia in Crohn’s disease: case report and literature review
por: Liu, Menghui, et al.
Publicado: (2019)

Over-reaching beyond disease activity: the influence of anxiety and medical economic burden on health-related quality of life in patients with inflammatory bowel disease
por: Luo, Xia-peng, et al.
Publicado: (2016)

Optimizing biologic treatment in IBD: objective measures, but when, how and how often?
por: Ben-Horin, Shomron, et al.
Publicado: (2015)

Thalidomide Prevented and Ameliorated Pathogenesis of Crohn’s Disease in Mice via Regulation of Inflammatory Response and Fibrosis
por: Chen, Hongjin, et al.
Publicado: (2019)

Magnetic resonance enterography in pregnant women with Crohn’s disease: case series and literature review
por: Stern, Myriam D, et al.
Publicado: (2014)

The Lewis score or the capsule endoscopy Crohn’s disease activity index: which one is better for the assessment of small bowel inflammation in established Crohn’s disease?
por: Yablecovitch, Doron, et al.
Publicado: (2018)

C-reactive protein/abumin ratio is a useful biomarker for predicting the mucosal healing in the Crohn disease: A retrospective study
por: Zhou, Fu-Sheng, et al.
Publicado: (2021)

Incidentally Diagnosed Asymptomatic Crohn’s Disease: A Retrospective Cohort Study of Long-Term Clinical Outcomes
por: Grinman, Ana, et al.
Publicado: (2022)

Comparison and development of machine learning for thalidomide-induced peripheral neuropathy prediction of refractory Crohn’s disease in Chinese population
por: Mao, Jing, et al.
Publicado: (2023)

Efficacy of thalidomide therapy in pediatric Crohn’s disease with evidence of tuberculosis
por: Wang, Lin, et al.
Publicado: (2017)

Self‐reported treatment effectiveness for Crohn's disease using a novel crowdsourcing web‐based platform
por: Engel, Tal, et al.
Publicado: (2023)

Structural robustness of the gut mucosal microbiota is associated with Crohn's disease remission after surgery
por: Mondot, S, et al.
Publicado: (2016)

Induction of Remission in Pediatric Crohn’s Disease Patients Assessed by the Mucosal Inflammation Noninvasive Index
por: Herman, Roma, et al.
Publicado: (2021)

Sustained remission of recalcitrant cutaneous lymphoid hyperplasia after thalidomide treatment
por: Erickson, Stephen P., et al.
Publicado: (2018)

Helicobacter pylori prevalence and clinical significance in patients with quiescent Crohn’s disease
por: Lahat, Adi, et al.
Publicado: (2017)

Association between Fecal Calprotectin and Mucosal Healing in Pediatric Patients with Crohn’s Disease Who Have Achieved Sustained Clinical Remission with Anti-Tumor Necrosis Factor Agents
por: Lee, Yoo Min, et al.
Publicado: (2022)

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial
por: Louis, Edouard, et al.
Publicado: (2023)

Fecal Calprotectin Assay at an Early Stage of Treatment Can Be Used as a Surrogate Marker to Predict Clinical Remission and Mucosal Healing in Pediatric Crohn’s Disease
por: Lee, Yeoun Joo, et al.
Publicado: (2022)

Risk factors and long-term outcome of disease extent progression in Asian patients with ulcerative colitis: a retrospective cohort study
por: Qiu, Yun, et al.
Publicado: (2019)

Targeting mucosal healing in Crohn’s disease: what the clinician needs to know
por: Klenske, Entcho, et al.
Publicado: (2019)

Mucosal Healing and Clinical Efficacy of Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA Study): Final Results From a Prospective, Open-Label, Single-Arm Study
por: Wetwittayakhlang, Panu, et al.
Publicado: (2023)

Machine learning for prediction of intra-abdominal abscesses in patients with Crohn’s disease visiting the emergency department
por: Levartovsky, Asaf, et al.
Publicado: (2021)

Oral exclusive enteral nutrition induces mucosal and transmural healing in patients with Crohn’s disease
por: Chen, Jia-Min, et al.
Publicado: (2019)

Comparison of transmural healing and mucosal healing as predictors of positive long-term outcomes in Crohn’s disease
por: Ma, Li, et al.
Publicado: (2021)

Predicting Mucosal Healing in Crohn’s Disease: A Nomogram Model Developed from a Retrospective Cohort
por: Tang, Nana, et al.
Publicado: (2022)

Anti-Saccharomyces cerevisiae Antibody in Pediatric Crohn’s Disease Patients without Mucosal Healing Is a Useful Marker of Mucosal Damage
por: Kim, Mi Jin, et al.
Publicado: (2021)

A New Way to Assess the Trajectory of Remission in Crohn Disease: Correlating Drug Levels With a Noninvasive Blood Biomarker of Mucosal Remission
por: Gremida, Anas, et al.
Publicado: (2021)

An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer
por: Drake, M J, et al.
Publicado: (2003)

Fecal calprotectin for detection of postoperative endoscopic recurrence in Crohn’s disease: systematic review and meta-analysis
por: Tham, Yuen Sau, et al.
Publicado: (2018)

Prediction of Recurrent Emergency Department Visits among Patients with Crohn’s Disease: A Retrospective Study
por: Mahajna, Hussein, et al.
Publicado: (2020)

Exploring the concept of deep remission in Crohn’s disease: correlation between transmural healing and biomarkers
por: Castiglione, Fabiana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_62mfc4ke4kb7i20tvan8mof6ea